Wednesday, November 7, 2012

Eli Lilly Japan and Chugai to Terminate Co-Marketing Agreement of “EVISTA® tablet 60mg,” a Treatment for Osteoporosis in Postmenopausal Women

Eli Lilly Japan K.K.and Chugai Pharmaceutical Co. Ltd. have agreed to terminate the agreement regarding co-marketing of “EVISTA® tablet 60mg” (raloxifene hydrochloride), a treatment for osteoporosis in postmenopausal women, as of December 31, 2012.
Lilly will be solely responsible for the distribution and commercialization of EVISTA® in Japan from January 2013. The termination will have no impact on Chugai's consolidated financial result in FY2012


Enter your email address:


Delivered by FeedBurner